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ABSTRACT
Roughly one third of the human population carries a latent
Mycobacterium tuberculosis infection, with a 5-10% lifetime risk of
reactivation to active tuberculosis and further spreading the disease.
The mechanisms leading to the reactivation of a latent
Mycobacterium tuberculosis infection are insufficiently understood.
Here, we used a natural fish pathogen, Mycobacterium marinum, to
model the reactivation of a mycobacterial infection in the adult
zebrafish (Danio rerio). A low-dose intraperitoneal injection (∼40
colony-forming units) led to a latent infection, with mycobacteria
found in well-organized granulomas surrounded by a thick layer of
fibrous tissue. A latent infection could be reactivated by oral
dexamethasone treatment, which led to disruption of the granuloma
structures and dissemination of bacteria. This was associated with
the depletion of lymphocytes, especially CD4+ T cells. Using this
model, we verified that ethambutol is effective against an active
disease but not a latent infection. In addition, we screened 15
mycobacterial antigens as postexposure DNA vaccines, of which
RpfB and MMAR_4207 reduced bacterial burdens upon reactivation,
as did the Ag85-ESAT-6 combination. In conclusion, the adult
zebrafish-M. marinum infection model provides a feasible tool
for examining the mechanisms of reactivation in mycobacterial
infections, and for screening vaccine and drug candidates.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
Tuberculosis (TB) remains one of the major global health problems.
Mycobacterium tuberculosis (Mtb), the causative agent of TB, led
to 1.4 million deaths and 10.4 million new infections in 2015
(WHO, 2017). The World Health Organization (WHO) estimates
that one third of the human population carries a latent TB infection,
and therefore has up to a 10% lifetime risk of it reactivating into an
active disease. Both vaccines and antibiotics have their limitations
in combating TB. Curative antibiotic treatments are lengthy and
further complicated by the emergence of multidrug-resistant Mtb
strains (WHO, 2017). The only available TB vaccine, Bacillus
Calmette Guérin (BCG), is still widely used. Although the BCG
vaccine can protect infants from disseminated TB, its ability to
induce long-term cell-mediated immune responses is limited, and
therefore it does not properly prevent the reactivation of a latent TB
infection (Tang et al., 2016). To reach the ambitious goal of
eliminating TB by the year 2050, innovative approaches are needed.
As nonhuman primates are the only animal models that
fully replicate all phases seen in human TB, it has been
challenging to study this area, especially the latency and
reactivation of mycobacterial infections (Capuano et al., 2003;
Myllymäki et al., 2015). It is known that reactivation of a latent
TB infection is often associated with immunosuppression, such
as human immunodeficiency virus (HIV), chemotherapy or
immunosuppressive drugs (Ai et al., 2016), but the more detailed
mechanisms of reactivation remain largely elusive on both the
bacterial and host side (Dutta and Karakousis, 2014; Peddireddy
et al., 2017). Considering the number of latent TB carriers,
preventing the reactivation of latent TB would be a key step in the
battle against TB (Matteelli et al., 2017).
During the past couple of decades, the zebrafish (Danio rerio) has
proven an applicable alternative for modeling TB (Myllymäki et al.,
2016). For this purpose, a natural fish pathogen and a close relative of
Mtb, Mycobacterium marinum, is used (Stinear et al., 2008).
Depending on the infectious dose, a M. marinum infection in adult
zebrafish can lead either to an active or to a naturally latent form of the
disease (Parikka et al., 2012; Swaim et al., 2006). In the latent form of
human TB, the bacteria are contained in structures termed granulomas,
which are surrounded by immune cells and a fibrotic capsule.
Although granulomas were long thought to be a protection method
elicited solely by the host, it has been found that they also promote
persistence of the bacteria (O’Garra et al., 2013; Davis and
Ramakrishnan, 2009). Upon a M. marinum infection, both adult
zebrafish and larvae form granulomas that are highly similar in
structure to those in humans (Parikka et al., 2012; Davis et al., 2002),
and the immune responses they elicit against mycobacteria share
similarities to those in humans (Parikka et al., 2012; Swaim et al.,
2006; Hammarén et al., 2014; Clay et al., 2008; Torraca et al., 2015;
Pagán et al., 2015; Yang et al., 2012). This has facilitated the
translation of some of the results from fish studies to humans (Tobin
et al., 2010; Adams et al., 2014; Berg et al., 2016; Thuong et al., 2017).
In the zebrafish, a latent mycobacterial infection can
spontaneously reactivate into an active disease (Hammarén et al.,Received 22 November 2017; Accepted 14 February 2018
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2014). In the current study, we have developed an experimental
method to reactivate a latent mycobacterial infection in the adult
zebrafish by feeding them the glucocorticoid dexamethasone. We
use this model for the characterization of the cellular and molecular
mechanisms associated with the reactivation of a mycobacterial
infection. In addition, we show that the model can be used in
screening for antibiotics and novel vaccine candidates against the
reactivation of a latent mycobacterial infection.
RESULTS
Dexamethasone treatment leads to an elevated bacterial
burden in zebrafish with a latent M. marinum infection
In humans, the reactivation of a latent TB infection often follows
immunosuppression. Similarly, immunosuppression by gamma
irradiation leads to the reactivation of a mycobacterial infection in
zebrafish (Parikka et al., 2012). To further study the mechanisms of
the reactivation of a mycobacterial infection in zebrafish, we tested
the effects of various immunosuppressive medicines on a latent M.
marinum infection (Fig. 1A). The fish were first infected with a low
dose of M. marinum, which leads to a latent infection in most fish,
and the immunosuppressive treatments were started 5 weeks later.
For this, we selected chemicals that are commonly used in humans
to alleviate excessive immune reactions associated with various
medical situations, such as organ transplantation, arthritis and
inflammatory bowel disease, and have been reported to increase risk
of the reactivation of TB in individuals with a latent infection (Jick
et al., 2006; Maltzman and Koretzky, 2003). The drugs included
azathioprine, dexamethasone, methylprednisolone and prednisolone.
To minimize additional stress, the drugs were administered orally, as
a gelatin mix that was used to coat the fish food pellets. The
experimental fish were treated with the drugs, 10 µg/fish/day, for
4 weeks, whereas the control fish received gelatin-coated food with
no chemicals. After the treatment, the fish were euthanized and the
DNA extracted from the intraperitoneal cavity of each fish was used
to determine the number of mycobacteria.
We found that feeding with dexamethasone led to an increase in
bacterial burdens (P=0.04, one-tailed Mann–Whitney test);
azathioprine produced a similar trend, though the increase was not
statistically significant (Fig. 1A). Within the anticipated dose of
10 µg/day, prednisolone and methylprednisolone did not lead to
elevated bacterial burdens. One fish from the control group and five
fish from the group fed with dexamethasone were euthanized
according to the humane endpoint criteria during the treatment –
these fish were also included in the analysis. Consistently, a high
number of mycobacteria [average of 2.9×106±4.8×105 colony-
forming units (cfu)] was detected in the euthanized fish (Fig. 1A),
suggesting that the signs of discomfort were due to the progression
of the M. marinum infection rather than the immunosuppression
itself. In line with this, the feeding of dexamethasone did not cause
signs of discomfort in uninfected fish. Therefore, the increase in the
bacterial counts following a dexamethasone treatment is likely to be
caused by the progression of a latent mycobacterial infection into an
active phase.
The kinetics of this progression were analyzed by measuring the
bacterial numbers at several time points following a dexamethasone
treatment in two independent experiments (Fig. 1B; Fig. S1A). An
increase in the bacterial burden was observed 3 days after the onset
of the feeding of dexamethasone (P=0.007, one-tailed Mann–
Whitney test), eventually leading to an approximately 1000-fold
increment at 4 weeks. A higher dose of dexamethasone (20 µg/day/
fish) had an essentially identical effect on bacterial numbers
(Fig. S1B). Therefore, the lower dose of dexamethasone (10 µg/day)
was selected for subsequent experiments. A pretreatment with
dexamethasone prior to infection did not affect the outcome of a low-
dose infection (Fig. S1C), suggesting that dexamethasone is more
likely to affect the host’s ability to control a latent infection than to
suppress the responses against mycobacteria during an early
infection. To obtain a more mechanistic insight into this, we next
investigated the cellular and molecular events associated with the
reactivation of a latent mycobacterial infection in the adult zebrafish.
Reactivation of a latent mycobacterial infection alters the
quality and quantity of granulomas
The formation of granulomas is defined as the hallmark of
tuberculosis, and granulomas also form in the adult zebrafish
during the course of an M. marinum infection. To demonstrate the
presence of granulomas during reactivation, we used Ziehl–Neelsen
staining to visualize mycobacteria in histological sections, and
trichrome staining to visualize the fibrous capsule typically found
around mature granulomas (Parikka et al., 2012). In fish with a
latent infection, the granulomas were generally well organized and
surrounded by a thick layer of fibrous tissue confining the
mycobacteria inside the granulomas (Fig. 2A). After 2 weeks of
dexamethasone treatment, the granulomas appeared larger and
looser in structure, showing thinning and disruption of the
Fig. 1. Dexamethasone treatment increases bacterial loads in adult
zebrafish with a latent M. marinum infection. (A) Zebrafish with a latent
mycobacterial infection were treated with immunosuppressants. Each dot
shows the bacterial count in one fish after 4 weeks of exposure to
immunosuppressive medication (10 µg/fish/day), (n=17-19 fish/group).
(B) Dots represent bacterial loads after 3, 7, 4 and 28 days of dexamethasone
treatment of fish with a latent mycobacterial infection (n=9-10 fish/group).
Horizontal lines represent the median bacterial count of each group.
Statistical significance was analyzed with the one-tailed Mann–Whitney test.
See also Fig. S1.
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surrounding fibrous layer. After 3 weeks of dexamethasone
treatment, further loss of granuloma integrity was observed,
together with bacteria escaping from the granulomas and
spreading into tissues, indicating progression of the infection into
an active state.
To quantify the dexamethasone-induced changes in the number
and types of granulomas, we counted the total number of
granulomas per fish at different time points during the treatment
(4, 14 and 21 days, n=3-6) (Fig. 2B). In the control group, the
number of granulomas remained relatively constant (average of 9-
17 granulomas/fish), while in the dexamethasone-treated group, the
number of granulomas increased from an average of 17 granulomas
at day 4 to an average of 57 granulomas per fish at 21 days. To
further characterize the process, we calculated the number of
Fig. 2. Dexamethasone treatment leads to disruption of the granuloma structure, increase in the number of granulomas and loss of hypoxia in
zebrafish with a latent mycobacterial infection. (A) Ziehl–Neelsen staining (ZN) of mycobacteria (purple). Black arrowheads indicate the outline of a
granuloma. Trichrome staining (TC) of fibrous tissue around granulomas (blue) (black arrows). (B) Quantification of the total number of granulomas and the
proportion of necrotic and non-necrotic granulomas (left), and the number of nascent granulomas and sites with non-capsulated mycobacteria (right) per fish after
4, 14 and 21 days of dexamethasone treatment or normal feeding (n=3-6 fish/group). Data are presented as mean±s.d. Statistical significance was assessed by
unpaired Student’s t-test. (C) Hypoxic staining shows hypoxic lesions inside granulomas in dark brown (pink stars). The proportions of hypoxic and non-hypoxic
granulomas during a latent infection, and after 2 weeks of dexamethasone treatment, are quantified in the pie chart. See also Fig. S2.
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necrotic (Fig. 2B) and multicentric granulomas separately
(Fig. S2A-C). Both are subtypes of mature granulomas that
contain a high number of mycobacteria, indicating an advanced
stage of a mycobacterial disease (Parikka et al., 2012). We found
that after 3 weeks of dexamethasone treatment, the number of
necrotic granulomas had increased from an average of 4.5 at day 4 to
27 at day 21 (P=0.02, one-tailed Mann–Whitney test) (Fig. 2B),
while there was also an increase in the number of multicentric
granulomas (Fig. S2B) and the proportion of necrotic versus
non-necrotic granulomas (Fig. S2C). Consistent with the qualitative
analysis, there was also a clear increase in the number of nascent
granulomas and sites with noncapsulated mycobacteria, from a
mean of 11 granulomas or sites at day 4 to 51 at day 21 (Fig. 2B).
This suggests that the treatment leads to the escape of mycobacteria
from existing granulomas and the seeding of new ones.
Hypoxia has been shown to have an important role in
mycobacterial pathogenesis. A low-oxygen environment induces
metabolic adaptation in bacteria, which allows the bacteria to persist
inside the host during a latent infection. To visualize hypoxic areas
in granulomas, pimonidazole treatment and Hypoxyprobe staining
were used (Fig. 2C) (Matty et al., 2015). Small hypoxic areas were
found adjacent to 25% of the granulomas in the fish with a latent
infection. Following a 21-day dexamethasone treatment, hypoxic
lesions were observed in only 8% of all granulomas (P<0.0001,
Fisher’s exact test) (Fig. 2C).
Altogether, these data suggest that during the reactivation of a
latent disease, mycobacteria first replicate within existing
granulomas. This leads to bacteria escaping and forming new
granulomas, as well as the appearance of free bacteria, which is
associated with the disruption of the granuloma structure and the
loss of hypoxia inside the granulomas.
Dexamethasone treatment leads to a decrease in the
amount of lymphocytes
Next, we investigated the alterations caused by dexamethasone in
immune cell populations in the kidney, which is the site of
hematopoiesis in the adult zebrafish. For this, we first treated wild-
type fish with dexamethasone for 1, 2 and 6 weeks and dissected
their kidneys for a flow cytometric [fluorescence-activated cell
sorting (FACS)] analysis. For the analysis, the cells in the live gate
were separated into populations based on size [defined by the
forward scatter (FSC)] and granularity [side scatter (SSC)]. These
included lymphocytes, granulocytes and monocytes, and blood cell
precursors. Upon dexamethasone treatment, the proportion of
lymphocytes decreased from 19.3±3.5% to 12.4±1.6% (P<0.01,
two-way ANOVA), while the relative amount of granulocytes and
monocytes and blood cell precursors remained unchanged (Fig. S3).
To study the effect of dexamethasone treatment on lymphocytes in
more detail, we used the Tg:lck(lck-EGFP) fish line, which
expresses GFP under the tyrosine kinase promoter specific for
mature T cells, NK-like cells and myeloid-like cells in the kidney of
adult zebrafish (Langenau et al., 2004; Carmona et al., 2017). lck-
GFP fish were treated with dexamethasone for 1, 2 and 4 weeks,
followed by FACS analysis of the kidney cell populations as above
(Fig. 3; Fig. S4B). As expected, the GFP+ cell population mainly
fell into the lymphocyte gate (Fig. 3A; Fig. S4B,C) (Langenau et al.,
2004). Again, upon dexamethasone treatment, the proportion of
lymphocytes decreased from 30.1±4.0% to 18.2±3.1% (P<0.001,
two-way ANOVA), while there was a slightly increasing trend in the
relative amount of granulocytes and monocytes and blood cell
precursors (Fig. 3B,C; Fig. S4B,C). More specifically, the
proportion of GFP+ lymphocytes decreased during the first week
of dexamethasone treatment, from the original 12.5±3.4% of live
cells in untreated fish to 6.3±2.4% (P<0.001, two-way ANOVA),
after which it remained the same throughout the treatment (Fig. 3D).
In addition, the GFP– lymphocyte population, which contains B
cells and immature T cells (Langenau et al., 2004), decreased from
18.5±2.8% to 10.3±1.7% of live cells (P<0.001, two-way ANOVA)
after 4 weeks of treatment (Fig. 3D). The proportion of GFP+
lymphocytes compared to GFP– ones decreased slightly at the 1-
and 2-week time points, but by 4 weeks, the GFP+: GFP– ratio had
returned to the same as that in the control group (40.2% and 43.0%
of GFP+ lymphocytes) (Fig. S4D).
Dexamethasone treatment alters the expression of T cell
markers upon infection
To further characterize the effects of dexamethasone treatment on
the immune response against mycobacteria, we compared the
kidney lymphocyte population of uninfected and infected wild-type
zebrafish after 1 week of treatment with dexamethasone (Fig. 4;
Fig. S5). A latent mycobacterial infection led to an increase in
the lymphocyte population (from 21.7±4.5% to 28.3±7.3%;
P<0.01, two-way ANOVA with Bonferroni posttest). Treating fish
with a latent infection with dexamethasone led to a decrease in
the proportion of lymphocytes, to the level seen in uninfected
fish (24.6±3.2%, P<0.05, two-way ANOVA with Bonferroni
posttest) (Fig. 4A).
To investigate the effect of dexamethasone on lymphocyte
function, we studied the expression levels of marker genes of
different types of T and B cells from the isolated kidney cells using
quantitative reverse transcription PCR (qRT-PCR) (Fig. 4B-G; Fig.
S5B-G). Of the studied inflammation markers, both tnfa and
interferon gamma 1-2 (ifng1-2; ifng-1) were induced in the fish
carrying a latent infection, with the former being slightly
upregulated (Fig. S5B), and the latter slightly downregulated
(Fig. 4B), by dexamethasone. The expression of tnfa correlated with
the bacterial burden (Spearman r 0.8180, P<0.0001), which likely
explains its relative elevation in the dexamethasone-treated
individuals, whereas no such correlation was observed for ifng1-2
expression (r –0.1740).
Zebrafish have CD4+ and CD8+ lymphocyte populations with
functions similar to those in humans (Langenau et al., 2004; Yoon
et al., 2015; Renshaw and Trede, 2012). Consistently, the expression
of both cd4-1 and cd4-2.1was induced upon infection (P=0.004 and
P=0.0002, respectively), whereas their expression was reduced
following dexamethasone treatment: cd4-1 was suppressed
following reactivation (P=0.0002) (Fig. 4C), and cd4-2.1 was
reduced in both uninfected (P=0.02) and infected (P=0.088) fish
(Fig. 4D). Expression of cd8a, a marker gene for cytotoxic T cells,
was induced in infected fish (P<0.0001), but its expression was not
altered by the dexamethasone treatment (Fig. 4E).
The balance between the CD4+ Th1 and Th2 cells has been
shown to play a role in the control of a mycobacterial infection
(Hammarén et al., 2014). To study the CD4+ subpopulation more
specifically, we used the expression of the tbx21 transcription factor
as a marker for the Th1 population, and the transcription factor
gata3 and il4, il10 and il13 as markers for Th2 cells. tbx21
expression was induced upon infection (P<0.0001) (Fig. 4F), as was
the expression of il10 (P=0.004) (Fig. S5C), while the expression
of the other Th2 markers tested remained relatively constant
(Fig. S5D,E). Dexamethasone treatment suppressed the expression
of tbx21 in uninfected fish (P=0.052) and in fish with a latent
infection (P=0.02) (Fig. 4F). Of the Th2 markers, a decreasing
expression for gata3 was seen after dexamethasone treatment in
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uninfected fish (P=0.03) and a corresponding trend was observed in
infected fish (Fig. 4G). The expression of IgM (ighm), which was
used as a marker for B cells, remained relatively constant in both
infected and dexamethasone-treated fish (Fig. S5F), whereas tgfb1b,
a marker for regulatory T cells (Tregs), was suppressed
upon infection in the immunocompetent fish (P=0.0007),
and upregulated in the dexamethasone-treated group (P=0.03)
(Fig. S5G). However, the expression of foxp3a, a transcription
factor characteristic for Tregs was not affected by dexamethasone
treatment (Fig. S4H).
Overall, these data indicate that a dexamethasone treatment leads
to the general depletion of lymphocytes. The most prominent effect
is seen in the expression of cd4-1, cd4-2.1 and the Th1 marker
tbx21. Although dexamethasone-treated fish are able to induce an
IFN-γ response against mycobacteria, the suppression of specific
T cell populations, together with the induction of the inhibitory
cytokine tgfb1b, are associated with compromised ability to control
infection.
The zebrafish model can be utilized to assess the efficacy of
drugs at different phases of a mycobacterial infection
Owing to their small size and fast reproduction rate, zebrafish are
well suited for large-scale pharmaceutical screening studies (Lohi
et al., 2013). On this premise, we investigated whether the
dexamethasone-based reactivation model can be used for testing
the effectiveness of antimicrobial medicines against reactivated
mycobacteria.
We chose four different antimicrobial drugs that have been
used for treating mycobacterial diseases, including ethambutol,
isoniazid, amikacin and metronidazole. Each of the antibiotics
Fig. 3. Dexamethasone treatment leads
to a depletion of lymphocytes in the adult
zebrafish. (A) Sorting of the kidney cell
populations of lck-GFP fish based on size
(side scatter, SSC-A) and granularity
(forward scatter, FSC-A) (left). The
lymphocyte population is further separated
into GFP+ and GFP– subpopulations
(middle), and the majority of the GFP– cells
fall into the lymphocyte gate by the SSC-A
and FSC-A. (B) After a 1-week
dexamethasone treatment, the kidney cells
fall into the same gates, but the number of
both GFP+ and GFP– lymphocytes is
depleted (right), as quantified in C and
D. n=12. Data are presented as mean±s.d.
Statistical significance is analyzed by two-
way ANOVA with Bonferroni posttest,
*P<0.05, **P<0.01, ***P<0.001. Also see
Figs S3 and S4.
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was first tested for their effect against M. marinum in vitro using
a bioluminescent strain, which allowed the quantification of
bacterial growth at different time points with a luminometer.
Two different doses were tested for each antimicrobial drug.
During the 7-day follow-up period, all antibiotics, excluding
isoniazid, inhibited the growth of M. marinum in a dose-
dependent manner, compared to bacteria cultured in medium
without antibiotics (Fig. 5A). Higher doses of ethambutol
(2.4 µg/ml), and amikacin (45.5 µg/ml), completely prevented
bacterial growth (P<0.05, respectively, one-way ANOVA with
Friedman’s test).
Next, zebrafish with a latent M. marinum infection were treated
for 3 weeks with dexamethasone, followed by 4 weeks of treatment
with antibiotics (50 µg/fish/day each). Metronidazole (160 µg/ml),
Fig. 4. Dexamethasone treatment
decreases the expression of CD4+ T
lymphocyte markers in uninfected and
infected zebrafish. (A) Lymphocytes are
expanded in the zebrafish kidney upon a
latent M. marinum infection and depleted
by dexamethasone treatment. The kidney
cell populations of AB fish were analyzed
with FACS. Bars show the mean
percentage of lymphocytes±s.d.
P-values were calculated using two-way
ANOVA with Bonferroni posttest,
*P<0.05, **P<0.01, ***P<0.001.
(B-G) Relative expression levels of
inflammatory genes and T cell markers.
Each dot represents the expression level
of the marker gene relative to the
housekeeping gene (EF1a). Horizontal
lines show the median value in each
group. n=10-11 fish/group. P-values were
calculated using the two-tailed Mann–
Whitney test. (B) ifng1-2, (C) cd4-1,
(D) cd4-2.1, (E) cd8a, (F) tbx21,
(G) gata3. See also Fig. S5.
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which is designed to target anaerobic microbes, inhibited the growth
of M. marinum in vitro by 48% compared to controls, but did not
limit the bacterial burden in vivo in a latent (Fig. S6A) or reactivated
infection (Fig. 5B).
However, ethambutol decreased the median bacterial counts in
dexamethasone-treated zebrafish by 96% compared to untreated
controls (P=0.01, Mann–Whitney test), which is close to the
level seen in a latent infection (Fig. 5B). Of note, a 2-week
treatment with ethambutol did not affect bacterial counts in
zebrafish with a latent M. marinum infection (Fig. S6B),
consistent with the knowledge that ethambutol acts by
preventing the replication of mycobacteria (Forbes et al., 1962).
This further demonstrates that dexamethasone treatment causes
the reactivation of a latent mycobacterial infection in zebrafish,
leading to the active replication of the bacteria and susceptibility
to ethambutol.
Identification of novel protective postexposure vaccine
antigens against the reactivation of TB in the zebrafish
model
We have previously shown that the zebrafish-M. marinum
infection model is suitable for the preclinical screening of
novel vaccine candidates against a mycobacterial infection
(Oksanen et al., 2013, 2016). The zebrafish can be partially
Fig. 5. Ethambutol inhibits the growth of M. marinum both in vitro and upon dexamethasone treatment in vivo. (A) The effects of selected antibiotics
on the growth of a bioluminescent strain of M. marinum in vitro. The graphs represent the detected relative bioluminescence (RLU) of bacteria at the indicated
time points after exposing them to an antibiotic. n=5-6. One-way ANOVA with Friedman’s test and Dunn’s multiple comparison test was used for statistical
analysis, *P<0.05, **P<0.01. (B) Adult zebrafish with a latent mycobacterial infection were treated for 3 weeks with dexamethasone (10 µg/fish/day) followed by
4 weeks of treatment with selected antibiotics. Each dot represents the bacterial burden per fish. Horizontal lines show the median value of each group. The
statistical analysis was performed with the two-tailed Mann–Whitney test.
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protected against a primary M. marinum infection by BCG, or by
prophylactic DNA-based vaccines consisting of a combination of
previously studied mycobacterial antigens (Ag85 and ESAT-6),
as well as with some novel antigens (Myllymäki et al., 2017).
Based on this, we studied the applicability of the dexamethasone-
based reactivation model for the preclinical screening of new DNA-
based vaccines by examining the therapeutic effect of the selected
mycobacterial antigens against the reactivation of a latent M.
marinum infection. The zebrafish were first infected with a low dose
of M. marinum, and vaccinated 5 weeks postinfection. Four weeks
after the vaccinations, the fish were subjected to dexamethasone
treatment (10 µg/fish/day) for 4 weeks, after which their bacterial
burdens were quantified by qPCR (the protocol is outlined in
Fig. 6). The antigens showing a significant reduction in bacterial
counts in the initial screen were subjected to a replicate experiment
to confirm the effect. We first tested the effect of the Ag85-ESAT-6
antigen combination against reactivation, and found that this
immunization decreased the bacterial counts by 56% or 0.35 log10
(P=0.02, two-tailed Mann–Whitney test) compared to the control
group immunized with an empty GFP plasmid (Fig. 7).
The other antigens tested involved genes from different
functional categories, including the four M. marinum
Resuscitation promoting factors (Rpf proteins), three members of
the PE/PPE protein family, four conserved membrane proteins, one
secreted factor and three metabolic enzymes. Compared to the GFP-
immunized control group, most of these did not affect the bacterial
burden of the fish upon reactivation. Noteworthy, immunization
with the antigens consisting of RpfB and MMAR_4207, led to a
significant reduction in bacterial counts (by 63% or 0.53 log10 and
85% or 0.81 log10, respectively) (Fig. 7).
Altogether, these data show that the dexamethasone-based
reactivation model provides an amenable tool for the preclinical
screening of both novel antimicrobials and therapeutic vaccines
against the reactivation of TB. For the latter, we identified two
promising candidates, RpfB and the conserved membrane protein
MMAR_4207.
DISCUSSION
TB remains a major health problem, and new antimicrobial
medicines and vaccines are needed to prevent new infections and
to prevent the reactivation of a latent TB infection (WHO, 2017).
During the past decade, the zebrafish, with its natural pathogen M.
marinum, has become a powerful model for studying the
mechanisms associated with mycobacterial defense as well as
new therapeutic strategies to fight mycobacterial infections. Some
of the results have been already translated into combatting human
TB infections (Adams et al., 2014; Tobin et al., 2013, 2012;
Oehlers et al., 2017). In the current study, we utilized the adult
zebrafish-M. marinum model to establish a tool for studying the
control and reactivation of latent mycobacterial infections. This
was achieved by the administration of the glucocorticoid
dexamethasone in the fish food. In humans, glucocorticoids are
used as immunosuppressants to treat various diseases, such as
arthritis, and long-term use at a high dose has been associated with
the reactivation of a latent TB infection, but the exact mechanisms
underlying the reactivation are poorly understood (Jick et al., 2006).
TB remains one of the major killers of HIV-coinfected
individuals: people with HIV are 20-30 times more likely to
develop active TB; and there were 0.4 million of such deaths in 2015
(WHO, 2017). In humans and macaques, an HIV or a Simian
immunodeficiency virus (SIV) infection is associated with the loss
of CD4+ T cells, which has long been thought to be the main factor
promoting the reactivation of a latent TB infection (Barnes et al.,
1991; Diedrich et al., 2010). This is also supported by data from the
mouse model (Kupz et al., 2016a,b). Using the adult zebrafish, we
observed a depletion of the lymphocyte population by
dexamethasone treatment in uninfected fish, and a failure to
induce lymphocyte expansion in infected fish. This is consistent
with the depletion of T cells by dexamethasone seen in zebrafish
larvae (Langenau et al., 2004). Moreover, our results suggest that
dexamethasone, in particular, decreases the amount of conventional
CD4+ lymphocytes, including both Th1 and Th2 cells, whereas the
expression of tgf-b1b, induced by the immunosuppressive Treg cell
population, is upregulated. Dexamethasone has been shown to
alleviate allergic symptoms in mice by upregulation of Treg cells
(Zhang et al., 2016), but the exact role of these cells and the
associated cytokines in the control of mycobacterial infections
remains to be studied.
Considering the functional similarities between human and
zebrafish CD4+ and CD8+ T cells (reviewed in Renshaw and
Trede, 2012), CD4+ cells could be a key player in controlling a
latent mycobacterial infection also in the zebrafish. However, the
susceptibility to the reactivation of a latent TB varies even among
HIV-coinfected individuals, and in a macaque model, CD8+ and B
cells have been shown to elicit a protective effect in some of the
coinfected individuals (Foreman et al., 2016). In the zebrafish, the
expression levels of cd8a and the B cell marker IgM remained
constant during the dexamethasone treatment, suggesting that
these cells are left unaffected by the treatment. Furthermore, the
individual zebrafish within a single line have been shown to differ
in their ability to control a mycobacterial infection, probably due
to genetic heterogeneity, leading to differences in the immune
response (Hammarén et al., 2014). We also observed that some
fish managed to maintain a relatively low mycobacterial count
despite the dexamethasone treatment, which could be explained
by the protective effect of CD8 and/or B cells, mimicking the
situation in humans and macaques (Foreman et al., 2016; van
Meijgaarden et al., 2015). The number of granulocytes and
monocytes was not decreased by dexamethasone. Macrophages
and neutrophils are needed for the formation of granulomas and
Fig. 6. Schematic representation of the experimental protocol for
testing vaccine candidates against the reactivation of a latent
mycobacterial infection. Fish with a latentM. marinum infection are
immunized with a DNA plasmid carrying a GFP-tagged mycobacterial
antigen, which allows detection of successful immunizations by
fluorescent microscopy. After 5 weeks, the fish are subjected to
dexamethasone treatment (10 μg/fish/day) for 4 weeks, followed by
determination of bacterial burdens by qPCR.
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for the early control of a mycobacterial infection (Davis et al.,
2002; Yang et al., 2012; Davis and Ramakrishnan, 2009).
Although treatment with dexamethasone prior to an infection
does not increase susceptibility to mycobacteriosis, but rather
compromises the control of a chronic infection, confirming that
dexamethasone does not affect the properties of macrophages or
Fig. 7. Ag85-ESAT-6, RpfB and MMAR_4207 antigens decrease bacterial burdens upon reactivation of a latent M. marinum infection in the adult
zebrafish. Fish with a latent M. marinum infection were immunized with the GFP control or experimental vaccines and 5 weeks later treated for 4 weeks with
dexamethasone. Each dot represents the bacterial load in one fish. Horizontal lines show the median values of pooled experiments (n=11-29 fish/group). Results
from different experiments are marked with different symbols. A two-tailed Mann–Whitney test was used to calculate P-values.
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neutrophils would require functional assays. In the infected,
dexamethasone-treated fish, we observed a strong negative
correlation (Spearman r –0.88, P=0.0007) between the bacterial
burden and the relative amount of macrophages and neutrophils in
the kidney, but it remains elusive whether there is any causal
relationship in either direction.
In adult zebrafish, granuloma structures reflect the stage of the
disease (Parikka et al., 2012), and, similar to observations in
macaques, rabbits and guinea pig, hypoxia is observed in granulomas
in adult zebrafish with a latent M. marinum infection, mainly in the
cells adjacent to necrotic areas (Via et al., 2008; Oehlers et al., 2015).
Upon reactivation, we observed loss of hypoxia, which was
associated with increasing granuloma counts, their necrosis and
multicentricity, and disruption of the surrounding fibrous capsule,
together with the emergence of disseminated bacteria at several sites
within tissues and the formation of nascent granulomas. The latter are
normally associated with a recent infection that has not yet reached a
latent stage (Parikka et al., 2012), but, in the context of
dexamethasone treatment, their appearance likely indicates
progression of the infection from a latent state into an active one.
As the mechanisms that trigger the exit of mycobacteria from the
granuloma remain largely elusive (Boggiano et al., 2017), this model
provides a feasible tool for examining the role of different immune
cells in the control of mycobacterial infections.
Owing to their cell wall properties and ability to persist inside
granuloma structures, mycobacteria have been a difficult pathogen
to target by current antibiotics (Peddireddy et al., 2017). Multidrug-
resistant strains present a further challenge for treatments, and new
antimicrobial drugs are therefore urgently needed (WHO, 2017).
We observed that ethambutol effectively prevented the growth ofM.
marinum in vitro, and after dexamethasone treatment, mycobacteria
could be successfully targeted in vivowith ethambutol, whereas a 2-
week treatment had no effect on a latent infection. Of the other
antibiotics tested in this study, a larger dose of amikacin could
inhibit mycobacterial growth in vitro, thus a larger dose could
improve the result in vivo as well. Metronidazole is designed to
exhibit its antibacterial activity under anaerobic conditions. It has
been shown to prevent the reactivation of latent TB in the macaque
model (Lin et al., 2012), but not in the guinea pig (Hoff et al., 2008),
and the human trial was discontinued owing to neurotoxicity
(Carroll et al., 2013). In our hands, metronidazole inhibited the
growth of M. marinum in vitro by ∼50%, but the tested dose was
ineffective against both a latent and a reactivated infection in
zebrafish. This could be due to a lack of anaerobiosis (despite the
presence of hypoxic lesions) in the zebrafish granulomas.
In previous studies, we showed that the zebrafish-M. marinum
infection model is feasible for use in the preclinical screening of
vaccines against a mycobacterial infection (Oksanen et al., 2013;
Myllymäki et al., 2017). This was also assessed in the current study
in the context of preventing reactivation of a latent mycobacterial
disease. We screened the effectiveness of an antigen combination
Ag85B-ESAT-6, which has been studied in HIV-positive Mtb
carriers (Reither et al., 2014), together with 15 novel conserved
mycobacterial antigens. We found that the Ag85B-ESAT-6
combination was able to improve the control of dexamethasone-
activated infection, reducing the median bacterial burden by 85%.
Importantly, two of the tested novel mycobacterial antigens, namely
RpfB and MMAR_4207, significantly decreased the bacterial
burden in the dexamethasone-treated fish. Their protective effect is
comparable to the effect of the BCG vaccination in a primary M.
marinum infection in the zebrafish (82% or 0.76 log10 reduction in
bacterial burden) (Oksanen et al., 2016), or an M. tuberculosis
infection in mice (0.35-1.2 log10 reduction in bacterial counts) (Jeon
et al., 2008). As its name implies, RpfB is thought to promote the
resuscitation and growth of dormant, nongrowing cells, and the
potential of the Rpf proteins as vaccine antigens has been studied to
some extent (Romano et al., 2012); thus, the promising result is not
completely unexpected. MMAR_4207 is a conserved membrane
protein with an unknown function, which makes this antigen an
interesting novel candidate for further studies. In our previous study,
these antigens did not affect the bacterial burden as prophylactic
vaccines in a primary infection assay (Myllymäki et al., 2017),
suggesting that they would more effectively target mycobacteria
upon reactivation. However, it is also possible that these vaccines
reduce the bacterial load during the latent phase of infection before
the immunosuppression takes place. Therefore, determining the
exact mechanism of their action requires further studies. Vaccine
candidates that elicit a strong CD4-based response generally provide
a rather low level of protection (Tameris et al., 2013; Sakai et al.,
2016), and, recently, other protection mechanisms, such as the
CD8+ and B cells and the humoral responses, have also received
attention (Achkar et al., 2015; vanMeijgaarden et al., 2015; Kamath
et al., 2006). A model system, where the CD4 arm of immunity is
hampered, could provide an interesting means to explore these.
Moreover, a therapeutic vaccine that would improve the control of a
latent TB, also in the immunocompromised, would be a great asset
in the battle against TB. Based on the results of this study, the
zebrafish model can provide a time- and cost-effective tool for the
early screening of such vaccine candidates, followed by studies in
larger animal models, such as macaque SIV-TB coinfection
(Diedrich et al., 2010; Foreman et al., 2016; Capuano et al., 2003).
In conclusion, the results of this study show that a latent M.
marinum infection can be reactivated with dexamethasone treatment
in the adult zebrafish. We used this method to characterize the
mechanisms associated with the process and found that in zebrafish,
like in humans, the depletion of lymphocytes, especially the CD4+ T
cell population, is associated with the impaired control of a latent
mycobacterial infection. This method also provides a tool for
screening the effectiveness of novel antimicrobial drugs and
vaccines against the reactivation of a latent mycobacterial
infection. Importantly, we identified two novel mycobacterial
antigens – RpfB and MMAR_4207 – that show protection against
the reactivation of a latent mycobacterial infection as postexposure
DNA vaccines.
MATERIALS AND METHODS
Zebrafish
In the experiments, 5- to 9-month-old, wild-type AB zebrafish (Danio rerio)
from the Tampere Zebrafish Core Facility were used. In addition, for the flow
cytometry, adult Tg:lck(lck-EGFP) fish [obtained from the Zebrafish
International Resource Center (ZIRC), University of Oregon, USA]
were used. Fish were maintained in a 10 h/14 h light/dark cycle, in a flow-
through salt water system at 28°C and were fed twice daily. The Animal
Experiment Board in Finland approved all animal experiments (ESAVI/8125/
04.10.07/2013) and studieswere carried out in accordancewith the EUdirective
2010/63/EU on the protection of animals used for scientific purposes. Humane
endpoint criteria were applied throughout all experiments, the wellbeing of the
fish was monitored carefully, and any fish showing signs of illness or
discomfort were immediately euthanized with 0.04% 3-aminobenzoic acid
ethyl ester pH 7.0 (A5040, Sigma-Aldrich, St Louis, MO, USA).
Experimental infections
TheM. marinum strain ATCC 927 was used for the infections. The culturing
of bacteria and infections were carried out as described earlier (Parikka et al.,
2012), except that bacteria were diluted with sterile 0.9× phosphate buffered
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saline (PBS) and 0.03 mg/ml Phenol Red before the infections. The
infection dose was 33±21 cfu/fish in all experiments, and was confirmed by
plating on 7H10Middlebrook OACD agar plates (BD Biosciences, Franklin
Lakes, NJ, USA).
Preparation and administration of medicine food
Immunosuppressive agents and antibiotics were administrated per os in the
fish food. The gelatin-coated fish food contained 2.5 mg/g of the
immunosuppressant or 12.5 mg/g of the antibiotics. Bovine gelatin
(G9391, Sigma-Aldrich; 400 mg) was diluted in 5 ml distilled water by
heating (45°C). Then, 25 mg of each immunosuppressant (azathioprine
A4638, dexamethasone D4902, prednisolone P6004 and
methylprednisolone M1755200, Sigma-Aldrich) or 125 mg of antibiotic
(ethambutol E4630, metronidazole M3761, isoniazid I3377 and amikacin
A0368000, Sigma-Aldrich) was mixed with 2 ml of 70% EtOH and the
suspension was combined with the gelatin solution. The gelatin mixture was
spread evenly on 10 g of dry fish food pellets (SDS400, Special Diet
Services, Essex, UK) and air dried overnight. The food was weighed and
homogenized using a mortar and a pestle. The increase in the weight of the
food, from the added gelatin and medicines, was taken in account when the
daily doses of prepared food were calculated and weighed, so that each fish
received 4 mg of food containing the desired dose of the drug. During the
reactivation treatments, the fish were fed once daily. The water circulation
was stopped during the feeding to avoid the spreading of chemical-
containing food into other tanks of the unit.
Histology
For histological staining, fish with a latent infection were treated with
dexamethasone (10 µg/fish/day) and samples were collected after 4, 14 and
21 days of treatment (n=3-6 fish/group). Untreated groups of fish were
collected as controls at each time point. The fish were euthanized with
0.04% 3-aminobenzoic acid ethyl ester (A5040, Sigma-Aldrich) and fixed
in 10% phosphate buffered formalin (Oy FF-Chemicals Ab, Haukipudas,
Finland) for 7 days. Decalcification, embedding into paraffin and the cutting
of sections were performed according to Parikka et al. (2012). Two parallel
5-µm sections were collected every 200 µm on two SuperFrost®Plus glasses
(Thermo Fisher Scientific), deparaffinized and used for either Ziehl–
Neelsen or trichrome staining. Ziehl–Neelsen staining was performed as
described in Parikka et al. (2012). The trichrome staining protocol was a
modified version from Mallory’s trichrome staining; before treatment with
acid fuchsin, the sections were incubated in Bouin’s solution (HT10132,
Sigma-Aldrich) overnight at room temperature. All slides were scanned with
an Olympus BX43 microscope and analyzed with the JPEG2000 virtual
slide and ImageJ software. Different types of granulomas (necrotic,
multicentric or nascent) and disseminated bacteria were classified
according to examples shown in Fig. S2A. Granulomas were counted
manually from each section to determine the total number of granulomas in
each fish (Oksanen et al., 2013).
Hypoxic lesions in granulomas were visualized with the HypoxyProbe-1
kit (HP1-100Kit, Hypoxyprobe, Burlington, MA, USA) in fish with a latent
infection and after 3 weeks of reactivation with dexamethasone. Fish were
anesthetized with 0.02% 3-aminobenzoic acid ethyl ester and
intraperitoneally injected with pimonidazole hydrochloride (60 µg/fish),
which forms covalent adducts with sulphydryl groups within protein
structures under hypoxic conditions. The fish were transferred to fresh water
for 5-10 min before euthanasia and histological sections were prepared as
described above. The staining followed the manufacturer’s instructions with
some modifications. Glasses were first deparaffinized and boiled in a
10 mM sodium citrate buffer with 0.05% Tween (pH 9) at 98°C for 15 min
to retrieve antigens. To block endogenous peroxidase activity, glasses were
treated for 5 min with 3% hydrogen peroxidase (88597, Sigma-Aldrich)
before a 1-h incubation with the primary antibody, a 1:600 dilution of
Hyproxyprobe-1 Mab1 (Batch No. 5.23.15). The secondary antibody,
universal immuno-enzyme polymer-peroxidase conjugate (mouse)
(414131F, Nichirei Biosciences Inc., Tokyo, Japan), was incubated for
30 min. For the staining reaction, 15 µl/ml of the chromogen (ImmPACT
DAP chromogen, Vector Laboratories, Burlingame, CA, USA) was mixed
with ImmDACT™ DAB (Vector Laboratories), and incubated for 5 min.
Mayer’s Hematoxylin solution (Reagena, Toivala, Finland) was used as a
counterstain for 2 min. TBS with 0.05% Tween buffer was used for all
washing steps and the staining was performed with a Autostainer 480
machine (Lab Vision, Thermo Fisher Scientific). Finally, glasses were
dehydrated within increasing alcohol series to xylene and embedded with
Coverquick 2000 (VWR Chemicals, Leuven, Belgium), and scanned as
described above. The total number of hypoxic and nonhypoxic granulomas
was counted from both groups (n=2 fish/group).
FACS
For the FACS analysis, wild-type AB fish and Tg:lck(lck-EGFP) fish were fed
with dexamethasone-containing food for the indicated times, together with an
untreated control group (12 fish/group); and latently infected and uninfected
AB fish were treated with dexamethasone or normal fish food for 1 week. Fish
were euthanized with 0.04% 3-aminobenzoic acid ethyl and their kidneys were
dissected in 500 µl of 0.5% fetal bovine serum (Sigma-Aldrich) in PBS on ice.
Tissues were homogenized and filtered through a 35 µm filter cap by
centrifugation at 200 g for 1 min. Cell sorting was performed with a
FACSCanto II device (Becton Dickinson Biosciences, San Jose, CA, USA)
and with the FACSDiva software (Becton Dickinson Biosciences). The
samples were run at medium speed (1000 events/s) and 20,000 events were
recorded for each sample, and used for the analysis of different cell populations
(lymphocytes, blood cell precursors, granulocytes and monocytes) based on
GFP expression, granularity and size with FlowJo software.
qPCR and qRT-PCR
Bacterial counts for each fish were obtained with qPCR (SensiFAST™
SYBR® No-ROX kit, Biolane Reagents Ltd, UK). The contents of the
intraperitoneal cavity from each fish was used for DNA extractions and the
Tri-reagent was used for the isolations as described previously (Parikka
et al., 2012). In qPCR, primers specific for the M. marinum internal
transcribed spacer forward (5′-CACCACGAGAAACACTCCAA-3′) and
reverse (5′-ACATCCCGAAACCAACAGAG-3′) were used. To exclude the
possibility of a backgroundM.marinum infection, a group of uninfected fish
treated with dexamethasone was also subjected to the qPRC analysis.
For the expression analysis of cytokines and T cell markers, whole
kidneys were dissected and used for RNA isolation with the RNeasy Mini
Kit (Qiagen). RNA samples were purified with the RapidOut DNase
Removal kit (Thermo Fischer Scientific) and then used for qRT-PCR
(SensiFAST™ SYBR No-ROX Kit, Biolane Reagents Ltd), according to
the manufacturer’s instructions. Expression levels of cytokines were
normalized to the expression level of elongation factor 1-alpha (EFa1;
eef1a1/1) in each sample. The primers used are shown in Table 1. The qPCR
was run with a Bio-Rad CFX96™ thermal cycler, and the data were
analyzed with the Bio-Rad CFX96™ Real Time System software.
Excluding the kidney, the rest of the internal organs were used for DNA
extraction and determining the bacterial counts as above.
In vitro antibiotic testing with a bioluminescent M. marinum
To test the effectiveness of antimicrobial drugs in vitro, we exposed a
bioluminescent M. marinum strain, ATCC BAA535, with the pMV306
plasmid (Addgene plasmid 26161), containing the LuxABDE cassette and
kanamycin resistance (Andreu et al., 2010), to different concentrations of
antibiotics (ethambutol E4630, metronidazole M3761, isoniazid I3377 and
amikacin A0368000, Sigma-Aldrich) and measured the light emitted by the
bacteria with a 2014 EnVision Multilabel Reader (PerkinElmer, Waltham,
MA,USA). Antibiotic concentrations were selected based on the literature (de
Steenwinkel et al., 2010). For each tested concentration, six replicate samples
were prepared in a white 96-well plate; in each well the desired antibiotic
dilution was added to 200 µl of a bacterial dilution (500 cfu/µl). Water was
used as a negative control. Mycobacteria were incubated at 29°C for 7 days
and the bioluminescence was measured on days 0, 1, 2, 3, 4 and 7. The results
were analyzed with EnVision Workstation 1.12 (PerkinElmer).
DNA vaccinations
DNAvaccine constructs were prepared as in former studies (Oksanen et al.,
2013; Myllymäki et al., 2017). Briefly, antigens were cloned into plasmids
(pCMV-EGFP, Addgene plasmid 11153) and transformed into chemically
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competent E. coli (One Shot TOP10 cells, Invitrogen). Plasmid DNA was
isolated with a Plasmid Plus Maxi Kit (Qiagen, Venlo, The Netherlands).
Fish were infected with a low dose of mycobacteria, and 5 weeks
postinfection vaccinated with 12 µg plasmid or a mixture of plasmids into
the dorsal muscle, followed by electroporation to the injection site (six
pulses of 40 V, 50 ms each) (Oksanen et al., 2013). The EGFP expression
of vaccine constructs was detected in each fish under UV light 5-7 days
postvaccination (Myllymäki et al., 2017). Five weeks postvaccination,
dexamethasone feeding (10 µg/fish/day) was started lasting for 4 weeks,
followed by determination of bacterial burden in each fish as described
above. In the primary screen, 11-18 fish per group were immunized with
the antigen candidates. Of these, the antigens leading to a significant
reduction in bacterial counts (two-tailed Mann–Whitney test) were chosen
for a replicate experiment with similar group sizes to confirm the original
result.
Statistical analyses and power calculations
Statistical analyses were carried out with GraphPad Prism 5 version 5.2
(Software Inc.). Bacterial burdens per fish were analyzed with the one- or
two-tailed Mann–Whitney test, and the granuloma counts were analyzed
with unpaired Student’s t-test and Fisher’s exact test of independence for
hypoxic and nonhypoxic granulomas. Two-way ANOVAwith a Bonferroni
posttest was used for the statistical analysis of the cell populations in the
FACS analysis, and the qRT-PCR results were analyzed with a two-tailed
Mann–Whitney test. The effectiveness of the antibiotics in vitro was
assessed with one-way ANOVAwith Friedman’s test. In each case, P<0.05
was considered significant. In the antibiotic and vaccine screening
experiments, the sample size of each group was determined based on
power calculations as in Myllymäki et al. (2017).
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(Tampere Tuberculosis Foundation; to M.R., M.P., H.M., M.N. and H.L.), Suomen
Kulttuurirahasto (Finnish Cultural Foundation; to H.M. and H.L.), Suomen
Tuberkuloosin Vastustamisyhdistyksen Säätiö (Finnish Anti-Tuberculosis
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Table 1. Primers used in qRT-PCR
Marker Forward primer Reverse primer
cd4-1 5′-CTGTTTCTGTTATAGACCTTGCC-3′ 5′-CTGGTCGGTCTTAAATGAAACT-3′
cd4-2.1 5′-CTTCAATGTCACTCTGATAAATGTGC-3′ 5′-TTACGTGCCGTGTAGATCTG-3′
cd8a 5′-GGAGTACCAGGTGGGCTTTT-3′ 5′-GAGGAAAAGTCCACAACCTC-3′
efa1 5′-CTGGAGGCCAGCTCAAACAT-3′ 5′-ATCAAGAAGAGTAGTACCGCTAGCATTAC-3′
foxp3a 5′-CAAAAGCAGAGTGCCAGTGG-3′ 5′-CGCATAAGCACCGATTCTGC-3′
gata3 5′-GGATGGCACCGGTCACTATT-3′ 5′-CAGCAGACAGCCTCCGTTT-3′
ifng1-2 5′-CTTTCCAGGCAAGAGTGCAGA-3′ 5′-TCAGCTCAAACAAAGCCTTTCG-3′
IgM 5′-AGATCCAATACAAAGATACTATGC-3′ 5′-TGGTGAAATGGAATTGTGG-3′
il10 5′-ATTTGTGGAGGGCTTTCCTT-3′ 5′-AGAGCTGTTGGCAGAATGGT-3′
il13 5′-GGAAGCTGTGTTAGTCAATCC-3′ 5′-GCCTGACAGAAATAATCATGC-3′
il4 5′-TGGTCCCCGTTTCTGAGTC-3′ 5′-ACCCTTCAAAGCCATTCCTG-3′
tbx21 5′-GGCCTACCAGAATGCAGACA-3′ 5′-GGTGCGTACAGCGTGTCATA-3′
tgfb1b 5′-CTGTTTGTACTGAAAAGTCTGAGG-3′ 5′-TCCAGACATAGGAGCAAGAGC-3′
tnfa 5′-GGGCAATCAACAAGATGGAAG-3′ 5′-GCAGGTGATGTGCAAAGACAC-3′
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Myllymäki, H., Bäuerlein, C. A. and Rämet, M. (2016). The zebrafish breathes new
life into the study of tuberculosis. Front. Immunol. 7, 196.
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